1. Targeted inhibition of Wnt signaling with a Clostridioides difficile toxin B fragment suppresses breast cancer tumor growth.
- Author
-
He, Aina, Tian, Songhai, Kopper, Oded, Horan, Daniel, Chen, Peng, Bronson, Roderick, Sheng, Ren, Wu, Hao, Sui, Lufei, Zhou, Kun, Tao, Liang, Wu, Quan, Huang, Yujing, Shen, Zan, Han, Sen, Chen, Xueqing, Chen, Hong, He, Xi, Robling, Alexander, Jin, Rongsheng, Clevers, Hans, Xiang, Dongxi, Li, Zhe, and Dong, Min
- Subjects
Humans ,Animals ,Mice ,Female ,Wnt Signaling Pathway ,Breast Neoplasms ,Bacterial Toxins ,Clostridioides difficile ,Cisplatin ,Mammary Neoplasms ,Animal - Abstract
Wnt signaling pathways are transmitted via 10 homologous frizzled receptors (FZD1-10) in humans. Reagents broadly inhibiting Wnt signaling pathways reduce growth and metastasis of many tumors, but their therapeutic development has been hampered by the side effect. Inhibitors targeting specific Wnt-FZD pair(s) enriched in cancer cells may reduce side effect, but the therapeutic effect of narrow-spectrum Wnt-FZD inhibitors remains to be established in vivo. Here, we developed a fragment of C. difficile toxin B (TcdBFBD), which recognizes and inhibits a subclass of FZDs, FZD1/2/7, and examined whether targeting this FZD subgroup may offer therapeutic benefits for treating breast cancer models in mice. Utilizing 2 basal-like and 1 luminal-like breast cancer models, we found that TcdBFBD reduces tumor-initiating cells and attenuates growth of basal-like mammary tumor organoids and xenografted tumors, without damaging Wnt-sensitive tissues such as bones in vivo. Furthermore, FZD1/2/7-positive cells are enriched in chemotherapy-resistant cells in both basal-like and luminal mammary tumors treated with cisplatin, and TcdBFBD synergizes strongly with cisplatin in inhibiting both tumor types. These data demonstrate the therapeutic value of narrow-spectrum Wnt signaling inhibitor in treating breast cancers.
- Published
- 2023